Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
Launched by YALE UNIVERSITY · Sep 20, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse," is designed to explore how improving sleep and emotional well-being can help adult smokers quit smoking. The researchers believe that by addressing negative feelings and enhancing self-control, they can better support people in their efforts to stop smoking. They will also look at how these changes are reflected in the brain using brain imaging techniques.
To participate in this study, you need to be between the ages of 18 and 62, have been a heavy smoker for over a year, and be able to read and understand English. You should also meet certain health criteria. However, if you are currently receiving treatment for smoking, have specific mental health issues, or are pregnant or nursing, you may not be eligible. If you join, you can expect to take part in behavioral interventions designed to help you quit, along with some assessments to track your progress. This study is not yet recruiting participants, but it aims to provide valuable insights into how sleep and emotional health can affect smoking cessation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English literate
- • report heavy tobacco use (including nicotine e-cigarettes) for \>6 months
- • meet biochemical cut off for recent cigarette smoking or e-cigarette use
- • optimal body mass index
- Exclusion Criteria:
- • currently enrolled in other treatments
- • neuropsychiatric exclusions that could interfere with study participation, increase risk of adverse events, and/or induce deficient sleep
- • medical contraindications for fMRI, varenicline, and/or behavioral treatment
- • factors that cause deficient sleep and for which behavioral treatment has less benefit
- • women who are pregnant or nursing
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Chiang-Shan Li
Principal Investigator
Yale University
Lisa Fucito, PhD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported